Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
about
Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressureAnacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk ReductionSegregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol.Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.Review of the quantitative analysis of cholesteryl ester transfer protein inhibitors.A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State.Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.The pharmacokinetics and pharmacokinetic/pharmacodynamic relationships of evacetrapib administered as monotherapy or in combination with statins.Applications of 'decisionable' biomarkers in cardiovascular drug development.Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.New horizons for cholesterol ester transfer protein inhibitors.Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies.Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.Off-Target Vascular Effects of Cholesteryl Ester Transfer Protein Inhibitors Involve Redox-Sensitive and Signal Transducer and Activator of Transcription 3-Dependent Pathways.Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor.Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects.Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination.
P2860
Q24624286-31549F20-D94D-4007-997C-A66FE81A6989Q29999973-5D669A2B-0D7C-4DE5-8742-B8CC9D617C4CQ34404589-E6129DB1-D24C-4718-AF0C-E51BD9891A94Q34571030-54F43709-EBEE-4696-ACF7-D5D59BC44744Q34708105-9280C660-66D5-462A-9794-C9E39150E3CBQ35953512-3C620443-1F0B-4F61-95CF-11EF519645D6Q36087976-BF5CAEEE-4F34-48AC-9C05-DCD09BA26C19Q36197709-A6AD0917-BADE-436B-9B45-3DF79185DE21Q37038670-0A683940-A152-4EF8-8392-B030BBB8FDF7Q37541793-231A9501-987A-410B-905F-491ED49039A0Q37816414-0614BA77-B3CF-451F-92E1-36B940128F03Q37826018-B7FE339C-72A9-4191-BF44-87CAF4E19B1BQ37941053-75670662-D08E-463F-ADF5-4F9E9F3C369DQ37956122-311B8BE8-5724-4E04-9253-A5D1F23D9B9CQ38098501-24FCC033-D451-465A-8F3B-A0E2C87C74FDQ38661093-26AE50DF-4AFC-43F7-B3EE-E8C26694FB12Q39010254-FD1D9A4E-27B2-4A35-8924-7C4DD6F79F52Q39949201-F6693F30-E986-4C07-B47F-CA16FA683EB7Q41479614-FEE7C698-7E26-48CC-9D11-ADB0D04BBB8EQ42725275-415122A4-AE19-4049-8FE6-6A0E2D9D5372Q47836018-13333353-7A25-4E3F-AB99-1ABCC67586D4Q50747614-D2B4B82A-8B70-43DB-9F72-8940D5CE4C94
P2860
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Single-dose pharmacokinetics a ...... inhibitor, in healthy subjects
@en
Single-dose pharmacokinetics a ...... nhibitor, in healthy subjects.
@nl
type
label
Single-dose pharmacokinetics a ...... inhibitor, in healthy subjects
@en
Single-dose pharmacokinetics a ...... nhibitor, in healthy subjects.
@nl
prefLabel
Single-dose pharmacokinetics a ...... inhibitor, in healthy subjects
@en
Single-dose pharmacokinetics a ...... nhibitor, in healthy subjects.
@nl
P2093
P2860
P1476
Single-dose pharmacokinetics a ...... inhibitor, in healthy subjects
@en
P2093
Arthur J Bergman
Cynthia Chavez-Eng
Deborah Hilliard
Deborah Panebianco
Jingjing Chen
John A Wagner
Josee Cote
Karen Snyder
P2860
P304
P356
10.1111/J.1365-2125.2009.03465.X
P407
P577
2009-10-01T00:00:00Z